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This editorial refers to ‘Mortality rates in patients with
ST-elevation vs. non-ST-elevation acute myocardial
infarction: observations from an unselected cohort’†
by C.J. Terkelsen et al., on page 18
Clinical registries have systematically shown that routine
clinical practice deals with sicker patients and faces
higher morbidity and mortality than the artiﬁcial
environment of strictly deﬁned randomized-controlled
trials might otherwise suggest.1–3 The series of Terkelsen
et al.,4 in the present issue of the European Heart
Journal, focuses on a cohort of 654 patients, represen-
ting all patients admitted to hospital for acute myocar-
dial infarction (AMI) from a catchments area of 139 000
inhabitants in Denmark. Their data are of particular
interest because (i) they constitute an attempt to
describe ‘real life’ in a comprehensive manner by target-
ing and checking all hospital admissions, rather than
relying on voluntary reports from selected participating
centres;1–3 and (ii) because angiographic and survival
status were obtained up to 1 year. Their analysis conﬁrms
the persistent high, in-hospital mortality of AMI in the
general population (14%), and also reveals three
main surprising facts: the median age of admitted
patients was advanced (73 years), the incidence of
non-ST-elevation myocardial infarction (NSTEMI) was
high (54% of all those diagnosed as AMI) and the prognosis
of NSTEMI (31% 1 year mortality) was worse than that of
STEMI (21% 1 year mortality).
The median age is clearly an important parameter to
keep in mind when assessing the signiﬁcance of a 14%
early mortality. In AMIS, GRACE and the EHS,1–3 the
mean age was under 70 in all three registries, and hospi-
tal mortality varied between 2.4 and 11.8% depending
on the subgroups considered. Older patients are often
excluded from randomized-controlled trials, and they
may also be more likely not to be entered into open
registries because of late arrival at hospital, death in
the emergency room or failure to be admitted to either
the ICU or the catheterization laboratory. The present
series reminds us that the elderly constitute a large—
and growing—subset of patients admitted to hospital for
AMI. Some of the other multivariate predictors of hospital
mortality also correspond to typical exclusion criteria
used in randomized trials: excessive delay in reaching
the hospital and azotaemia are good examples. Thus,
for registry data to be adequately assessed, investigators
need to remember that acquisition of sufﬁcient infor-
mation concerning essential cardiac and non-cardiac
parameters is of major importance: the very factors
that exclude patients from randomized trials are often
those with the greatest impact on clinical outcome.
Both acute management and discharge treatment
reported in the series by Terkelsen et al.4 are probably
a good reﬂection of the average European approach.
Only 48% of patients with NSTEMI beneﬁted from an
early invasive strategy, however, and only 35–51% of
patients were discharged with lipid-lowering therapy.
Both of these can be seen as less than optimal in view
of current knowledge and may have also contributed to
the high observed mortality.
STEMI vs. NSTEMI
ST-segment elevation on the ECG is usually ascribed
to a transmural current of injury leading to an
outward-directed ST vector, whereas ST depression is
more often associated with subendocardial ischaemia
and an inward-directed vector.5 However, both the speci-
ﬁcity and the sensitivity of these changes can be pro-
foundly altered by several factors such as prior
myocardial infarction or bypass surgery, location of the
ischaemic territory, variations in coronary anatomy,
pre-existing bundle branch block, etc.6 Because of the
amount of myocardium involved, one would logically
expect transmural ischaemia to be associated with a
more unfavourable prognosis, but the very opposite was
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shown in the study by Terkelsen et al.,4 where the
unadjusted 1 year mortality was 30.5% for NSTEMI and
20.5% for STEMI. Even more signiﬁcant, was the
fact that NSTEMI (vs. STEMI) remained an independent
predictor of 1 year mortality in a multivariate analysis,
together with advanced age, renal failure, prior heart
failure, depressed left ventricular ejection fraction,
and prolonged pre-hospital delay. Other registries have
differed: in the Euro Heart Survey2 early in-hospital mor-
tality was 7% for STEMI and only 2.8% for NSTEMI, and in
GRACE3 the ﬁgures were 7% for STEMI and 6% for NSTEMI,
respectively. Clearly, a diagnosis of NSTEMI covers a very
broad spectrum of coronary diseases ranging from
minimal myocardial damage with single vessel disease
in relatively young and otherwise healthy patients, to
more important acute myocardial damage associated
with diffuse coronary atherosclerosis and extensive
pre-existing myocardial dysfunction. Depending on the
patient mix that is being considered, both acute and
longer-term outcomes are bound to be very different.
Acute haemodynamic status
The major missing cardiovascular parameter in the series
by Terkelsen et al.4 is the clinical haemodynamic status
at admission. The Killip scoring system has been available
to clinicians for over 35 years7 and has repeatedly been
shown to be an extremely powerful predictor of
short-term mortality.8 It is therefore possible that the
list of multivariate predictors in the Danish series might
have been different if this information had been col-
lected at admission by the investigators. For patients
with STEMI in the AMIS registry,1 the likelihood of dying
in hospital was six times higher when shock (Killip IV)
was present at admission, and 3.6 times higher when pul-
monary oedema (Killip III) was diagnosed. In the SHOCK
trial registry,8 152 patients with AMI and early cardio-
genic shock had no ST-segment elevation on the presen-
ting ECG; they represented 17% of the 881 patients
included in the registry and were older, with more prior
AMI, heart failure, renal failure, bypass surgery and per-
ipheral vascular disease than the patients with STEMI.
They also had lower peak creatinine kinase (CK) values,
more frequently suffered from triple vessel disease, and
the left circumﬂex artery was more often the culprit
vessel for the acute event. In-hospital mortality for
NSTEMI patients was 62.5%, nearly identical to the
60.4% observed for patients with STEMI. The clinical
proﬁle of the two groups of patients in the SHOCK registry
is thus quite similar to those observed by Terkelsen
et al.,4 and a pattern, probably best applicable to regis-
tries, can be seen to emerge: younger patients with less
prior cardiac and non-cardiac events in their medical
history (‘the rookie hearts’) tend more frequently to
present with transmural ischaemia when they are
admitted for AMI and have more acute myocardial
damage as shown by higher peak CK values; conversely,
older patients who more frequently have suffered prior
damage to their left ventricle, and also have more
non-cardiac morbidity (‘the veteran hearts’), tend to
have less acute myocardial damage and no ST-segment
elevation, but a similar or worse prognosis, both
acutely and after follow-up at 1 year.
The practical conclusions are obvious: the vast
majority of patients with NSTEMI who are appropriate
candidates should be treated aggressively and early in
their clinical course, since their prognosis is probably
similar to, or worse than, those with STEMI. This usually
means rapid referral for invasive investigation in view
of timely coronary revascularization.9 On average,
there may be less myocardium at stake for the ‘veterans’
than for the ‘rookies’, but not necessarily less clinical
beneﬁt.
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